Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
FINGERPRINT STUDY OF 1000 SINGAPOREANS SHOWS HIGH SELF-MANAGEMENT AND RESILIENCE TRAITS: BRILLIANAIRE 2024-08-23 13:46
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization 2024-08-23 12:32
Getinge to acquire Paragonix Technologies, a growth leader in the organ transplantation market 2024-08-23 05:00
Alzheimer's Association Commends United Kingdom's Approval of Leqembi, But Condemns Decision to Deny NHS Access 2024-08-23 00:31
Ascentage Pharma Announces 2024 Interim Results 2024-08-22 23:36
Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program 2024-08-22 21:30
Ubie Announces Social Impact Framework, Shows Estimated Patient Life Expectancy Impact of 27,000 Years and Approximately $1BN 2024-08-22 21:30
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA 2024-08-22 21:04
Stem Cell Therapy developers I Peace and iCamuno Biotherapeutics Start Natural Killer Cell Trial for Ovarian Cancer 2024-08-22 21:00
Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy 2024-08-22 20:00
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1 2024-08-22 18:00
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities 2024-08-22 17:04
Inaugural Process Innovation Asia Pacific to Drive Industry Transformation for South-East Asia's Chemicals and Pharmaceuticals 2024-08-22 15:30
Chen Institute and Science to Hold Innovative Conference in Shanghai Spotlighting Latest Developments in "Artificial Intelligence and Mental Health" 2024-08-22 13:00
China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China 2024-08-22 08:00
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16 2024-08-22 08:00
Eyebright Medical Announces Strong First Half 2024 Results, with Revenue Surpassing 68% Growth and Net Profit Rising by Nearly 30% 2024-08-22 00:00
WuXi Biologics Reports Solid 2024 Interim Results 2024-08-21 23:46
Sisram Medical Announces First-Half 2024 Financial Results 2024-08-21 21:53
UTime Limited Announces Ambitious AI Health Strategy and Strategic Collaboration 2024-08-21 21:25
1 42 43 44 45 46 1619